Analysis of the prevalence trend of drug resistance among high risk population of multi drug resistant-tuberculosis in Wuhan from 2007 to 2020

WANG Jian-jie; ZHOU Mei-lan; REN Xin; WU Gang; ZHANG Zheng-bin; TIAN Dan; WANG Xiao-jun; LI Yue-hua

doi:10.16462/j.cnki.zhjbkz.2022.11.020

Volume 26 Issue 11

Nov. 2022

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2022 > 26(11): 1353-1359

WANG Jian-jie, ZHOU Mei-lan, REN Xin, WU Gang, ZHANG Zheng-bin, TIAN Dan, WANG Xiao-jun, LI Yue-hua. Analysis of the prevalence trend of drug resistance among high risk population of multi drug resistant-tuberculosis in Wuhan from 2007 to 2020[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(11): 1353-1359. doi: 10.16462/j.cnki.zhjbkz.2022.11.020

Citation:

WANG Jian-jie, ZHOU Mei-lan, REN Xin, WU Gang, ZHANG Zheng-bin, TIAN Dan, WANG Xiao-jun, LI Yue-hua. Analysis of the prevalence trend of drug resistance among high risk population of multi drug resistant-tuberculosis in Wuhan from 2007 to 2020[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(11): 1353-1359. doi: 10.16462/j.cnki.zhjbkz.2022.11.020

Citation:

WANG Jian-jie, ZHOU Mei-lan, REN Xin, WU Gang, ZHANG Zheng-bin, TIAN Dan, WANG Xiao-jun, LI Yue-hua. Analysis of the prevalence trend of drug resistance among high risk population of multi drug resistant-tuberculosis in Wuhan from 2007 to 2020[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(11): 1353-1359. doi: 10.16462/j.cnki.zhjbkz.2022.11.020

PDF( 2381 KB)

Analysis of the prevalence trend of drug resistance among high risk population of multi drug resistant-tuberculosis in Wuhan from 2007 to 2020

doi: 10.16462/j.cnki.zhjbkz.2022.11.020

Department of the TB Control, Wuhan Pulmonary Hospital, Wuhan 430030, China

Funds:

Scientific research project of Hubei Provincial Health Commission WJ2021F011

More Information

Corresponding author: LI Yue-hua, E-mail: 664748060@qq.com
Received Date: 2022-01-27
Rev Recd Date: 2022-05-18

Available Online: 2022-12-21

Publish Date: 2022-11-10

Abstract

Abstract

Objective To retrospectively analyze the drug resistance prevalence trend of drug resistance-tuberculosis(DR-TB) high-risk populations in Wuhan from 2007 to 2020. Methods From January 1, 2007 to December 31, 2020, a total of 5 139 at risk individuals of DR-TB newly registered in Wuhan were screened. By carrying out a descriptive study, χ² test and multivariate unconditional logistic regression, the prevalence trend and influencing factors of drug resistance were analyzed. Results The overall drug resistance rate among these individuals was 35.51% (1 600/4 506). The ranking of resistance rates of six different anti-TB drugs was as following, Isoniazid (H)>Rifampin (R)>Streptomycin (S)>Ofloxacin (O)>ethambutol (E)>Kanamycin (K). From 2007 to 2020, except the O resistance rate, the overall drug resistance rate, multidrug resistance rate, drug resistance rates of H, R, E, S and K showed an upward trend (R resistance rate: P=0.002, all the others have P < 0.001). From 2015 to 2020, except an upward trend was observed in R resistance rate (P=0.002), the overall drug resistance rate, multidrug resistance rate and drug resistance rates of H, E, S, O and K remained stable. Conclusions From 2007 to 2020, an upward trend of drug resistance among Wuhan's DR-TB at risk populations was observed. Although no upward trend was observed in the period between 2015 and 2020, further strengthening of management and control of such groups is still urgently needed.
- Mycobacterium,
- Tuberculosis,
- Drug resistance,
- Trend,
- Influential factors

FullText(HTML)

References(12)

References

[1]	WHO. Global tuberculosis report 2021[EB/OL]. (2021-10-14)[2022-03-01]. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021.
[2]	中国全球基金结核病项目办公室. 中国全球基金结核病项目(一期)实施细则耐多药结核病防治领域[M]. 北京: 北京大学医学出版社, 2010: 31-39. China Global Fund TB Project Office. Implementation details of China Global Fund Tuberculosis Project (phase I)[M]. Beijing: Peking University Medical Press, 2010: 31-39.
[3]	唐神结, 许绍发, 李亮. 耐药结核病学[M]. 北京: 人民卫生出版社, 2014: 321-324. Tang SJ, Xu SF, Li L. Drug-Resistant Tuberculosis[M]. Beijing: People's Medical Publishing House, 2014: 321-324.
[4]	赵亚玲, 黎舒, 邱媛. 2012-2016年南宁市耐多药肺结核高危人群筛查情况分析[J]. 应用预防医学, 2019, 25(1): 14-17. https://www.cnki.com.cn/Article/CJFDTOTAL-GXYX201901004.htm Zhao YL, Li S, Qiu Y. Screening of multi-drug resistance pulmonary tuberculosis in hi-gh-risk group, Nanning, 2012-2016[J]. Applied Prev Med, 2019, 25(1): 14-17. https://www.cnki.com.cn/Article/CJFDTOTAL-GXYX201901004.htm
[5]	李佳, 黄玲, 赵玉杭, 等. 福州市2016-2020年耐药肺结核发现情况分析[J]. 中国热带医学, 2021, 21(8): 795-799. DOI: 10.13604/j.cnki.46-1064/r.2021.08.16. Li J, Huang L, Zhao YH, et al. Analysis of drug-resistant pulmonary tuberculosis in Fu-zhou 2016-2020[J]. Chin Trop Med, 2021, 21(8): 795-799. DOI: 10.13604/j.cnki.46-1064/r.2021.08.16.
[6]	王坚杰, 周美兰, 段琼红, 等. 2010年湖北省武汉市第5次结核病流行病学抽样调查分析[J]. 中华疾病控制杂志, 2014, 18(4): 326-329. http://zhjbkz.ahmu.edu.cn/article/id/JBKZ201404014 Wang JJ, Zhou ML, Duan QH, et al. The fifth tuberculosis epidemiological survey of Wuhan City in 2010[J]. Chin J Dis Control Prev, 2014, 18(4): 326-329. http://zhjbkz.ahmu.edu.cn/article/id/JBKZ201404014
[7]	李永文, 李新旭, 耿红, 等. 山东省结核分枝杆菌的耐药流行状况[J]. 中华结核和呼吸杂志, 2013, 36(9): 667-670. DOI: 10.3760/cma.j.issn.1001-0939.2013.09.007. Li YW, Li XX, Gen H, et al. Epidemic status of drug-resistant Mycobacterium tubercul-osis in Shandong Province, China[J]. Chin J Tuberc Respir Dis, 2013, 36(9): 667-670. DOI: 10.3760/cma.j.issn.1001-0939.2013.09.007.
[8]	中华人民共和国卫生部. 全国结核病耐药性基线调查报告(2007-2008年)[M]. 北京: 人民卫生出版社, 2010: 33. Ministry of Health, PRC. National baseline survey of tuberculosis drug resistance (2007-2008)[M]. Beijing: People's Medical Publishing House, 2010: 33.
[9]	许可, 丁松宁, 杨晨, 等. 使用倾向得分匹配法评估南京市耐多药结核病的影响因素[J]. 中华疾病控制杂志, 2022, 26(3): 285-289. DOI: 10.16462/j.cnki.zhjbkz.2022.03.008. Xu K, Ding SN, Yang C, et al. Evaluating the influential factors of multidrug-resistant t-uberculosis using a propensity score matching method[J]. Chin J Dis Control Prev, 2022, 26(3): 285-289. DOI: 10.16462/j.cnki.zhjbkz.2022.03.008.
[10]	Lee EG, Min J, Kang JY, et al. Age-stratified anti-tuberculosis drug resistance profiles i-n South Korea: a multicenter retrospective study[J]. BMC Infect Dis. 2020, 23(1): 446-455. DOI: 10.1186/s12879-020-05157-6.
[11]	李君, 朱小梅, 毛玲琼, 等. 温州市2014-2015年耐多药肺结核高危人群筛查情况分析[J]. 中国公共卫生管理, 2017, 33(3): 345-347. DOI: 10.19568/j.cnki.23-1318.2017.03.017. Li J, Zhu XM, Mao LQ, et al. Screening of multi-drug resistance pulmonary tubercu-losis in high-risk group, Wenzhou, 2014-2015[J]. Chin J of PHM, 2017, 33(3): 345-347. DOI: 10.19568/j.cnki.23-1318.2017.03.017.
[12]	王坚杰, 周美兰, 杜义祥, 等. 武汉市耐药/耐多药结核病影响因素分析[J]. 中华疾病控制杂志, 2017, 21(2): 164-167. DOI: 10.16462/j.cnki.zhjbkz.2017.02.014. Wang JJ, Zhou ML, Du YX, et al. Analysis on the influential factors of drug resistance and multidrug resistant tuberculosis in Wuhan City[J]. Chin J Dis Control Prev, 2017, 21(2): 164-167. DOI: 10.16462/j.cnki.zhjbkz.2017.02.014.